Skip to Content

ABP 215 Approval Status

ABP 215 (bevacizumab) is an anti-vascular endothelial growth factor A (anti-VEGF) monoclonal antibody biosimilar to Avastin (bevacizumab) in development for the treatment of non-squamous non-small cell lung cancer (NSCLC) and other cancers.

Development Status and FDA Approval Process for ABP 215

DateArticle
Nov 15, 2016Amgen and Allergan Submit Biosimilar BLA for ABP 215 to U.S. FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide